Alkermes (NASDAQ:ALKS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

by · The Cerbat Gem

Alkermes (NASDAQ:ALKS – Get Free Report) had its price objective raised by equities research analysts at Royal Bank Of Canada from $56.00 to $57.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price indicates a potential upside of 26.23% from the company’s current price.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group began coverage on shares of Alkermes in a report on Thursday, September 24th. They issued a “neutral” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Alkermes from $60.00 to $61.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Mizuho upgraded shares of Alkermes to a “strong-buy” rating in a research report on Wednesday, September 16th. HC Wainwright boosted their price target on Alkermes from $43.00 to $50.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Stifel Nicolaus reissued a “buy” rating and set a $63.00 price target (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.06.

View Our Latest Stock Report on Alkermes

Alkermes Stock Performance

Shares of ALKS traded down $0.54 during midday trading on Wednesday, reaching $45.16. 345,585 shares of the stock were exchanged, compared to its average volume of 2,120,254. The stock’s 50 day simple moving average is $43.92 and its 200 day simple moving average is $40.59. The company has a market cap of $7.58 billion, a P/E ratio of 119.04 and a beta of 0.32. Alkermes has a twelve month low of $27.00 and a twelve month high of $55.67. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82.

Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.17. Alkermes had a net margin of 3.96% and a return on equity of 4.15%. The business had revenue of $480.13 million for the quarter, compared to the consensus estimate of $463.48 million. During the same period in the prior year, the company posted $0.49 earnings per share. Alkermes’s revenue was up 21.8% compared to the same quarter last year. On average, sell-side analysts expect that Alkermes will post -0.57 earnings per share for the current year.

Insider Activity at Alkermes

In related news, SVP Christian Nichols sold 7,576 shares of Alkermes stock in a transaction on Monday, August 17th. The shares were sold at an average price of $49.23, for a total transaction of $372,966.48. Following the completion of the transaction, the senior vice president owned 102,193 shares of the company’s stock, valued at $5,030,961.39. This trade represents a 6.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president directly owned 219,353 shares in the company, valued at $10,127,528.01. This represents a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,679 shares of company stock worth $1,070,940 over the last three months. Company insiders own 4.59% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA lifted its holdings in shares of Alkermes by 20.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,009,318 shares of the company’s stock worth $41,012,000 after purchasing an additional 171,292 shares in the last quarter. CenterBook Partners LP grew its stake in shares of Alkermes by 88.3% in the 3rd quarter. CenterBook Partners LP now owns 13,938 shares of the company’s stock worth $565,000 after acquiring an additional 6,535 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Alkermes in the 3rd quarter valued at about $347,000. Profund Advisors LLC increased its position in shares of Alkermes by 38.5% during the third quarter. Profund Advisors LLC now owns 55,421 shares of the company’s stock valued at $2,246,000 after acquiring an additional 15,394 shares during the last quarter. Finally, Choreo LLC raised its stake in shares of Alkermes by 3.1% during the 3rd quarter. Choreo LLC now owns 26,611 shares of the company’s stock worth $1,078,000 after purchasing an additional 796 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

  • Positive Sentiment: Alkermes reported third-quarter EPS of $0.09, versus analyst expectations for a $0.08 loss, while revenue of $480.1 million topped estimates of $463.5 million and rose 21.8% year over year. The results may bolster confidence in business performance. Article: Alkermes Reports Third Quarter 2026 Financial Results
  • Positive Sentiment: HC Wainwright raised its price target from $43 to $50, implying roughly 9.4% upside from the cited $45.69 share price. Its rating remains neutral, tempering the significance of the higher target. HC Wainwright ratings
  • Neutral Sentiment: The company reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton in mid-2027. Maintaining guidance provides visibility, while the clinical update remains a future catalyst. Article: Alkermes reiterates outlook and targets mid-2027 Phase III data
  • Neutral Sentiment: EVP David Gaffin sold 2,035 shares, about 0.92% of his holdings, under a pre-arranged Rule 10b5-1 plan. The scheduled nature of the sale makes it less indicative of a change in his outlook. SEC Form 4
  • Negative Sentiment: Despite beating expectations, quarterly EPS fell from $0.49 a year earlier to $0.09, a year-over-year decline that could limit enthusiasm about the results. Article: Alkermes Q3 earnings metrics

About Alkermes

(Get Free Report)

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.

Further Reading